Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates

Pavla Pokorná, Martin Šíma*, Birgit Koch, Dick Tibboel, Ondřej Slanař

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)

Abstract

Introduction: Sufentanil is a potent synthetic opioid used for analgesia in neonates; however, data concerning drug disposition of sufentanil and dosage regimen are sparse in this population. Therefore, the aim of the study was to explore sufentanil disposition and to propose optimal loading and maintenance doses of sufentanil in ventilated full-term neonates. Methods: Individual sufentanil pharmacokinetic parameters were calculated based on therapeutic drug monitoring data using a 2-compartmental model. Linear regression models were used to explore the covariates. Results: The median (IQR) central volume of distribution (Vdc) and clearance (CL) for sufentanil were 4.7 (4.1-5.4) L/kg and 0.651 (0.433-0.751) L/h/kg, respectively. Linear regression models showed relationship between Vdc (L) and GA (r2 = 0.3436; p = 0.0452) as well as BW (r2 = 0.4019; p = 0.0268). Median optimal sufentanil LD and MD were 2.13 (95% CI: 1.78-2.48) μg/kg and 0.29 (95% CI: 0.22-0.37) μg/kg/h, respectively. Median daily COMFORT-B (IQR) scores ranged from 6 to 23 while no significant relationship between pharmacokinetic parameters and COMFORT-B scores was found. Discussion/Conclusion: Body weight and gestational age were found as weak covariates for sufentanil distribution, and the dosage regimen was developed for a prospective trial.

Original languageEnglish
Pages (from-to)384-389
Number of pages6
JournalPharmacology
Volume106
Issue number7-8
DOIs
Publication statusPublished - 1 Jul 2021

Bibliographical note

Funding Information:
This work was supported by the Ministry of Health of the Czech Republic project MH CZ-DRO-VFN64165, by the Charles University project PROGRES Q25/LF1 and SVV 260523, by an unrestricted research grant of the Intensive Care Unit of the Erasmus MC-Sophia Children’s Hospital, and by the project UNCE204064 (the Innovative Medicines Initiative 2, Grant Agreement No. 777389 from the European Union’s Horizon 2020 and EFPIA).

Publisher Copyright:
© 2021 The Author(s) Published by S. Karger AG, Basel.

Fingerprint

Dive into the research topics of 'Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates'. Together they form a unique fingerprint.

Cite this